4599.T
StemRIM Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 146.00
−0.68%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- +10.1%
- EPS
- +13.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +109.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- +5.4%
- EBIT
- +5.1%
- Net income
- +4.6%
- EPS
- +5.5%
- Free cash flow
- +22.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jan 1, 2026